Other News

Neovasc Announces US$72 Million Registered Direct Offering Priced At-The-Market

Vancouver, Canada, Feb. 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 […]

Itamar Medical Announces Closing of Public Offering of American Depositary Shares and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

CAESAREA, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the closing of its public […]

CARMAT Reports Its Financial Results for 2020, and Confirms Its 2021 Prospects

CE marking in the bridge to transplant indication received in December 2020 Operating expenses under control at €36m Financial resources including cash position of €36m at December 31, 2020, providing financial visibility until Q3 2021 Company actively reviewing options to fund its development beyond Q3 2021 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT […]

CARMAT Receives FDA Approval to Use the New Version of Its Artificial Heart in the US Early Feasibility Study (EFS)

First enrollment in the study expected in Q1 2021 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today provides […]

InterShunt Technologies Announces Expansion of Board of Directors and Opening of Minneapolis Facility

PLYMOUTH, Minn., Feb. 9, 2021 /PRNewswire/ — InterShunt Technologies, Inc., an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced today the appointment of key members to the company’s Board of Directors.  Jim Bullock, David Adair, MD, MBA, and Denis Harrington join current Board Directors Harlee Sorkin, CEO […]

First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Europe has been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS). Professor Nicolas Van […]

PhysIQ and U.S. Veteran’s Affairs Advance to Interventional Trial Phase

CHICAGO–(BUSINESS WIRE)–physIQ, Inc. and the US Department of Veteran’s Affairs (VA) have advanced their collaboration to address heart failure care to an interventional trial phase. In this next phase, Veterans will be actively monitored so care can be administered in near real-time to avoid or lower the chance of re-hospitalization, […]

Positive Preliminary Clinical Trial Results Reported for Vascular Dynamics’ Novel Heart Failure Treatment Technology

Endovascular baroreflex modulation data presented IRVINE, Calif.–(BUSINESS WIRE)–Vascular Dynamics, Inc., a privately held medical device company focused on innovative, endovascular device-based solutions for cardiovascular conditions, has announced positive preliminary results from its clinical trial, “A Feasibility Study Exploring the Effect of the MobiusHD® Device in Patients with Heart Failure.” Horst Sievert, […]

Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock at a public offering price of $70.00 per share, including 535,714 shares sold pursuant […]